• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
    • Corporate Videos
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Investor Conference Calls  
    • Company Reports
    • Presentations
    • Research
    • News & Media
    • Fact Sheets
    • Right to Receive Documents
  • Contact

News &
Media

  • Neurotech International announces breakthrough results from autism study

    8 July 2022
    Cannabiz

    Neurotech International has announced breakthrough results from a clinical trial of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).

    View More
  • Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis study

    8 July 2022
    The Market Herald

    Neurotech International (NTI) has reported that 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with autism spectrum disorder (ASD).

    View More
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug

    8 July 2022
    The Sentiment

    The cannabinoid based drug, licensed from Dolve Cann Global is the world’s first full-spectrum medicinal cannabis product (with less than 0.3% THC).

    View More
  • Neurotech tackles the anguish of autism with low-THC cannabis treatment

    1 July 2022
    Stockhead

    A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.

    View More
  • RSH, AVR, NTI: Best performing ASX healthcare equipment stocks in June

    28 June 2022
    Kalkine Media

    Neurotech is conducting clinical studies to assess the anti-inflammatory, neuroprotective, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.

    View More
  • Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour

    17 June 2022
    Stockhead

    The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.

    View More
  • Neurotech International reports positive preclinical data from combination study

    14 June 2022
    BiotechDispatch

    Neurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.

    View More
  • ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac

    9 June 2022
    Stockhead

    Neurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.

    View More
  • Neurotech International (ASX:NTI) sees preclinical success with combination therapies

    9 June 2022
    The Market Herald

    Neurotech International (NTI) has reported preclinical research demonstrating its proprietary cannabis strain can improve Diclofenac efficacy at low doses.

    View More
Previous
1 2 3 4 5 6
Next

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1702130863anoit1702130863anret1702130863nihce1702130863torue1702130863n@ofn1702130863i1702130863

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus